Glaxosmithkline Pharmaceuticals Ltd
About
GlaxoSmithKline Pharmaceuticals is a subsidiary of the GSK Group in India. Its objective is to get ahead of disease with the help of science, talent, and technology and touch the lives of 2.5 billion people in the next 10 years. After its demerger with Haleon, a consumer healthcare business, GlaxoSmithKline Pharmaceuticals has become a fully focused biopharma company. Its R&D team focuses on the immune system, human genetics, and advanced technologies, primarily in the domain of 4 therapeutic areas: infectious diseases, HIV, oncology, and immunology. GSK’s offerings have been divided into 3 verticals, namely general medicines, vaccines, and specialty medicines. While general medicines cover anti-infectives, pain, dermatology, and vitamins, specialty medicines are targeted at respiratory diseases and HIV. GSK has 60+ vaccines in the pipeline but currently markets 10 for infants, adolescents, and adults.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 3660 11.0% | 3297 -29.6% | 4685 47.3% | 3182 -18.1% | 3886 19.4% | 3254 8.4% | 3002 1.9% | 2946 -5.6% | 3122 -11.0% | 3509 24.5% | 2818 1.7% | 2771 5.9% | 2616 13.6% | 2302 10.7% | 2079 3.4% | 2011 - |
| Net Operating Income (INR Cr) | 3454 6.21% | 3252 -0.80% | 3278 12.05% | 2926 -9.27% | 3224 3.08% | 3128 8.94% | 2871 -1.27% | 2908 2.49% | 2838 -14.12% | 3305 28.95% | 2563 -3.17% | 2647 9.62% | 2414 12.24% | 2151 12.63% | 1910 12.41% | 1699 6.04% |
| Profit (INR Cr) | 590 -3.4% | 611 -64.0% | 1695 373.2% | 358 284.3% | 93 -79.1% | 445 27.0% | 351 4.1% | 337 -10.5% | 376 -21.1% | 476 -1.1% | 482 -14.3% | 562 31.1% | 429 -23.5% | 561 10.4% | 508 -14.1% | 591 - |
| Assets (INR Cr) | 2044 1.6% | 2012 -31.7% | 2947 66.1% | 1774 -16.0% | 2111 -14.1% | 2457 4.7% | 2348 2.8% | 2284 -7.8% | 2476 17.4% | 2110 -5.9% | 2241 -0.5% | 2252 3.8% | 2170 10.9% | 1957 9.2% | 1792 13.3% | 1581 - |
| Net Worth (INR Cr) | 1778 2.1% | 1741 -34.6% | 2663 80.1% | 1478 -18.8% | 1821 -14.9% | 2140 4.0% | 2057 2.5% | 2007 -8.1% | 2183 19.4% | 1829 -8.1% | 1990 -0.9% | 2007 3.7% | 1936 -0.8% | 1952 9.3% | 1786 13.4% | 1576 14.1% |
| Employee Cost (INR Cr) | 624 4.9% | 595 -2.5% | 610 -1.0% | 616 -2.0% | 629 17.0% | 537 2.6% | 523 8.4% | 483 8.9% | 443 -10.1% | 493 36.2% | 362 -8.0% | 394 36.9% | 287 22.6% | 235 15.0% | 204 21.2% | 168 - |
| Interest Cost (INR Cr) | 2 | 2 | 2 | 4 | 6 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Cash & Bank Balance (INR Cr) | 1063 | 1156 | 2485 | 1158 | 1083 | 1171 | 1296 | 900 | 1392 | 1911 | 2042 | 2067 | 2014 | 2003 | 1734 | 957 |
| Total Debt (INR Cr) | 19 | 16 | 20 | 35 | 0 | 1 | 1 | 2 | 2 | 3 | 4 | 5 | 5 | 5 | 5 | 6 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 16.1% | 18.5% | 36.2% | 11.3% | 2.4% | 13.7% | 11.7% | 11.4% | 12.1% | 13.6% | 17.1% | 20.3% | 16.4% | 24.4% | 24.4% | 29.4% |
| Profit As % Of Assets | 28.9% | 30.4% | 57.5% | 20.2% | 4.4% | 18.1% | 14.9% | 14.8% | 15.2% | 22.6% | 21.5% | 25.0% | 19.8% | 28.7% | 28.4% | 37.4% |
| Profit As % Of Networth | 33.2% | 35.1% | 63.6% | 24.2% | 5.1% | 20.8% | 17.1% | 16.8% | 17.2% | 26.1% | 24.2% | 28.0% | 22.1% | 28.7% | 28.4% | 37.5% |
| Interest Cost to EBITDA % | 0.2% | 0.2% | 0.3% | 0.9% | - | 0.1% | 0.0% | 0.1% | 0.1% | 0.1% | 0.1% | - | 0.1% | 0.1% | 0.1% | 0.1% |
| Debt to Equity Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| RONW | 37.3% | 27.7% | 81.3% | 28.9% | 10.0% | 21.2% | 17.3% | 16.1% | 18.8% | 20.0% | 24.1% | 33.3% | 30.2% | 30.0% | 30.2% | 34.1% |
| ROCE | 45.0% | 33.9% | 32.6% | 32.4% | 28.5% | 28.4% | 23.3% | 21.5% | 25.2% | 27.8% | 31.7% | 44.4% | 45.0% | 45.1% | 46.0% | 47.3% |